This phase II trial tests whether oral iloprost works in preventing lung cancer (chemoprevention) in former smokers. Oral iloprost has previously been shown to reduce abnormal lung cells in former smokers, suggesting a clinically significant impact on lung cancer risk. The use of oral iloprost may help keep cancer from forming and reduce abnormal cells in the lung in order to lower the risk of developing lung cancer in former smokers.

开始日期2024-06-01

申办/合作机构

National Cancer Institute

NCT06319274

/ Recruiting临床2期IIT

Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 ng/kg/Min) in Mechanically Ventilated Patients With Infectious Pulmonary Endotheliopathy - a Multicenter Randomized, Placebo-controlled, Blinded, Investigator-initiated Trial

The purpose of this clinical trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in 450 mechanically ventilated patients with infectious respiratory failure. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in patients suffering from respiratory failure caused by endothelial breakdown, ultimately improving survival.

开始日期2024-04-15

申办/合作机构

Rigshospitalet

NCT05938946

/ Completed临床1期

A Phase I, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of L608 for Inhalation in Healthy Subjects

This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.

开始日期2023-08-30

申办/合作机构

国邑药品科技股份有限公司

[+1]

100 项与伊洛前列素相关的临床结果

登录后查看更多信息

100 项与伊洛前列素相关的转化医学

登录后查看更多信息

100 项与伊洛前列素相关的专利（医药）

登录后查看更多信息

3,368

项与伊洛前列素相关的文献（医药）

2025-07-01·AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial

Article

作者: Bounes, Fanny ; Kimmoun, Antoine ; Ellrodt, Olivier ; Jullien, Edouard ; Legrand, Matthieu ; Gaugain, Samuel ; Barraud, Damien ; Dépret, François ; Pottecher, Julien ; Plantefève, Gaëtan ; Jamme, Matthieu ; Auvet, Adrien ; Juguet, William ; Leone, Marc ; Fedou, Anne-Laure ; Audibert, Juliette ; Ait-Oufella, Hafid ; Lefebvre, Laurent ; Poncelin de Raucourt, Yves ; Chen, David ; Sonneville, Romain ; Vicaut, Eric ; Lasocki, Sigismond ; Geri, Guillaume ; Constantin, Jean-Michel ; Abrard, Stanislas ; Guerci, Philippe

Rationale: Preclinical and preliminary clinical data suggest that iloprost may improve tissue perfusion in septic shock. However, its effect on organ failure remains unclear. Objectives: To investigate whether iloprost provides organ protection in septic shock with hypoperfusion. Methods: In this multicenter, double-blind, randomized controlled trial, adults with septic shock and persistent hypoperfusion (i.e., increased capillary refill time and/or skin mottling) were randomized to receive a 48-hour intravenous infusion of iloprost or placebo. The primary outcome was the change in the Sequential Organ Failure Assessment (SOFA) score from randomization to Day 7. Secondary outcomes included mortality at Day 28, organ support-free days by Day 28, and mean daily SOFA score. Measurements and Main Results: A total of 240 patients were randomized, and 236 were included in the analysis. Median (IQR) changes in SOFA score were -4 (-7 to 7) in the iloprost group and -5 (-8 to 5) in the placebo group (median difference, 1; 95% CI, 0-3; P = 0.12). At 28 days, 48 patients (42%) had died in the iloprost group and 47 (39%) had died in the placebo group (relative risk, 1.08; 95% CI, 0.80-1.5). The median average SOFA score was 11.2 (7.4-15.9) in the iloprost group, compared with 10.5 (6.8-16.5) in the placebo group (median difference, 0.25; 95% CI, -1.1 to 1.8). Median (95% confidence interval) between-group differences in 28-day ventilation-, vasopressor-, and renal replacement therapy-free survival days were 0 (0-0), 0 (-1 to 1), and 0 (0-0), respectively. Severe adverse events occurred in 15% of patients in the iloprost group and 7% of patients in the placebo group (P = 0.06). Conclusions: Among patients with septic shock and persistent hypoperfusion, iloprost did not reduce the severity of organ failure. Clinical trial registered with www.clinicaltrials.gov (NCT03788837) and EudraCT (2018-001709-10).

2025-06-03·RHEUMATOLOGY

Long-term effects of selexipag in systemic sclerosis-associated digital ulcers: a case control multicentre observational study.

Article

作者: Tavoni, Antonio G ; Caporali, Roberto ; Della Rossa, Alessandra ; Di Battista, Marco ; Sette, Manuel ; Cavalli, Silvia ; Mosca, Marta ; Del Papa, Nicoletta ; Bochicchio, Cristina ; Cacciapaglia, Fabio ; Giuggioli, Dilia ; Minniti, Antonina ; Stano, Stefano ; Armentaro, Giuseppe ; Pellico, M R ; Magi, Ilaria ; Giudice, Laura ; Orlandi, Martina ; Iannone, Claudia

OBJECTIVES:

Digital ulcers (DUs) affect ∼50% of systemic sclerosis (SSc) patients, causing significant pain and functional impairment. Current management involves both systemic and local therapies. However, the burden in terms of pain and quality of life due to refractory DUs still remains heavy. While selexipag is approved for SSc-associated pulmonary arterial hypertension, its potential in treating DUs is unexplored. We aimed to evaluate the long-term efficacy of selexipag compared with iloprost in treating DUs.

METHODS:

In this multicentre case-control study, we retrospectively evaluated 96 SSc patients with refractory DUs (32 treated with selexipag, 64 with iloprost), matched for gender, disease subset, and age. DU number, ischemic pain and Raynaud phenomenon (RP) severity were assessed at baseline, 6, 12, and 24 months. Pain and RP were evaluated using the Likert Pain Scale (LPS) and Raynaud Condition Score (RCS), respectively. Additionally, DUs recurrence and new onset were recorded. Healing rates were estimated using Kaplan-Meier analysis.

RESULTS:

Selexipag showed higher efficacy with 87% of DUs healing rate vs 28% for iloprost at 96 weeks (p< 0.001). DUs number, RCS, and LPS showed significant improvement in selexipag-treated patients compared with iloprost (p< 0.001 for all) throughout 24 months. Selexipag-treated patients achieved faster healing (75% by week 40) and maintained significantly lower relapse rates (5% vs 45% at 24 months, p< 0.001). New DUs formation remained consistently lower in the selexipag group compared with the iloprost group (5% vs 40% at 24 months, p< 0.001).

CONCLUSIONS:

This observational study suggests that selexipag may be strongly effective in treating DUs refractory to conventional drugs.

2025-06-01·ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

Management of hypertensive leg ulcers: A French national survey

Article

作者: Nguyen-Chi, H ; Tella, E ; Zerdani, Y ; Senet, P ; Monfort, J-B ; Mahé, E

BACKGROUND:

Hypertensive leg ulcers (HLUs) are superficial, rapidly spreading, necrotic ulcers that are frequently resistant to standard local wound care. The available literature on HLU management is relatively poor. This survey-based study aimed to evaluate the management of HLUs in France.

METHODS:

A questionnaire was sent in December 2019 to all members of the Angiodermatology Group of the French Society of Dermatology. The questionnaire collected information about physicians and their department, and about their management of HLUs, including examinations and specific and non-specific topical and systemic treatments.

RESULTS:

Forty-four physicians responded. The most frequently performed examinations were lower-limb arterial Doppler (88.6%), ankle-brachial pressure index tests (83.7%) and venous Doppler (60.5%). Blood sampling for autoimmunity testing was requested by 27.3% of physicians and skin biopsy by 20.5%. The most frequently used first-line therapy was skin grafting (97.7%). Other treatments included topical steroids (58.1%), negative-pressure therapy (15.9%), electrostimulation (15.9%), auto-haemotherapy (14.0%), and iloprost (11.4%). The mechanism of action of electrostimulation is not very clear. Its main benefit lies in controlling the pain of HLU. Iloprost appears to be an interesting vasodilator although it has not been validated to date. An additional antiplatelet agent was proposed by 19.0% of the physicians and modification of anticoagulant treatment (use of a vitamin K antagonist in addition to direct oral anticoagulants) was proposed by 19.5% of physicians.

DISCUSSION:

The survey results showed that HLU evaluation involved searching for associated peripheral arterial disease and that HLU management in France was disparate. Skin grafting was the sole consensual treatment and was generally used as a first-line option. Other treatments require further evaluation. Management disparities could be reduced by the drafting and publication of a consensus guideline to harmonise HLU management.

项与伊洛前列素相关的新闻（医药）

2025-05-17

·梅斯医学

一运动就气喘不已，误以为是体弱，医生却告诉他患上了心血管系统的癌症，误诊率高达90%

21岁的小王，从小就是大家眼里的“体弱生”——不爱运动，走路慢，爬楼梯总是落在最后。小学体育课他跑不过女生，初中篮球赛常常还没上场就已经喘得满脸通红。老师觉得他“娇气”，同学以为他“懒”，连家人也只是当他“锻炼太少”。“我真不是不想跑，我是真的跑不动。”小王总是这样解释，但没人相信。直到上大学军训，他因为短短的五分钟小跑突然脸色苍白、呼吸困难，甚至差点晕倒，被紧急送医。医生听诊发现他心音异常，进一步检查中血氧偏低、心电图提示右心负荷过重，心脏超声也显示右心扩大。肺部CT正常，但超声心动图提示肺动脉收缩压升高，右心导管检查证实：小王患上的是一种罕见而严重的心肺疾病——特发性肺动脉高压（IPAH）。特发性肺动脉高压特发性肺动脉高压（idiopathic pulmonary arterial hypertension，IPAH）指一类无明确原因、以肺血管阻力进行性升高为主要特征的恶性肺血管疾病，不伴随任何可能导致该种情况的基础疾病，患者往往合并不同程度右心功能衰竭甚至死亡。欧美注册登记研究结果表明，平均诊断年龄为50～65岁.男女发病率为1:2～3。欧洲资料显示,成年人特发性肺动脉高压的患病率约为5.9/100万。我国缺乏特发性肺动脉高压流行病学数据，患者以中青年女性为主，平均诊断年龄约为36岁。我国学者研究表明，仅接受传统药物治疗，特发性肺动脉高压与家族性肺动脉高压患者1年、3年、5年的生存率分别为68%、38.9%、20.8%。临床表现原发性肺动脉高压（IPAH）的临床表现与其他类型的肺动脉高压相似，症状和体征缺乏特异性。最常见的症状是活动后气短，此外还可出现乏力、头晕、胸痛、胸闷、心悸、黑矇和晕厥等。特别是当出现晕厥或眩晕时，提示患者的心搏量可能已明显下降，病情较为严重。由于缺乏特异性的症状和体征，绝大多数患者的就诊存在明显延迟。研究显示，至少有五分之一的患者从症状出现到确诊的时间超过两年；超过一半的IPAH患者在确诊时已处于WHO功能分级的Ⅲ～Ⅳ级阶段，提示病情在确诊时往往已较为严重。IPAH的体征主要与肺动脉压力升高和右心衰竭有关。肺动脉压力升高时，可听到肺动脉瓣第二心音亢进，三尖瓣关闭不全可引起三尖瓣区的收缩期杂音。右心衰竭的体征则包括颈静脉充盈或怒张、肝脏肿大、下肢水肿、多浆膜腔积液，以及在晚期可能出现的黄疸和发绀等表现。诊断IPAH的初步检查包括血常规、心电图、X线等，可提示肺动脉高压迹象。进一步评估需进行血气分析、肺功能、CT、超声心动图、右心导管检查等。血液检查中，血红蛋白常因缺氧升高，脑钠肽水平升高提示病情加重。血气分析多见低氧血症，二氧化碳分压下降。影像学方面，X线可见肺动脉增粗，CT用于排查肺间质病变和肺血管畸形，核素肺通气/灌注显像在筛查慢性肺血栓性疾病中较敏感。超声心动图可评估肺动脉压和右心功能，是常用筛查手段。右心导管检查是诊断IPAH的金标准。静息时平均肺动脉压≥25 mmHg、肺动脉楔压≤15 mmHg、肺血管阻力＞3 Wood单位可确诊。检查时应排除其他引起肺高压的病因，如心肺疾病、结缔组织病、药物或毒物暴露等。诊断需结合病史、临床表现和多项检查结果，遵循标准流程，排除继发性肺动脉高压，方可确诊IPAH。治疗IPAH是一种进展性、不可逆的疾病，目前尚无法根治。治疗目标主要是降低肺循环阻力，改善右心功能、提升运动耐量和延长生存期。治疗可分为三大方面：一般治疗包括指导适度体力活动和康复训练、避免妊娠、预防感染、提供心理和社会支持、加强依从性管理，以及必要的遗传咨询。同时建议使用华法林抗凝，并在条件允许时转诊至专业的肺动脉高压中心。药物治疗前需通过右心导管检查进行风险评估及急性血管扩张试验，选择个体化药物方案。急性扩张试验阳性的患者可使用高剂量钙通道阻滞剂。其余常用靶向药物包括磷酸二酯酶-5抑制剂（如西地那非、他达拉非）、内皮素受体拮抗剂（如波生坦、安立生坦、马西替坦）、前列环素类药物（如伊洛前列素、瑞莫杜林）、可溶性鸟苷酸环化酶激动剂（如利奥西呱）和前列环素受体激动剂赛乐西帕。手术治疗适用于病情严重、药物无效的患者。球囊扩张房间隔造口术可作为姑息性治疗或肺移植前的过渡措施。肺移植或心肺联合移植虽风险较高，但目前是唯一可能实现根治的治疗方式。参考资料：[1]中华医学会呼吸病学分会肺栓塞与中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血病防治协作组，等.中国肺动脉高压诊华医学杂志，2021，101(1):11-51[2]Hassoun P M, Taichman D B. Pulmonary Arterial Hypertension[J]. New England J Med, 2021, 385(25):2361-2376.[3]Humbert M, Kovacs G, Hoeper M M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43(38):3618-3731.来源 | 梅斯医学编辑 | wanny神经系统罕见病交流群↓点击下方“阅读原文”，下载梅斯医学APP吧！

2025-05-05

·喜鹊医药公司

世界肺动脉高压日 | 关于PAH，你了解多少？

点击蓝字关注我们肺动脉高压（PAH）是一种罕见、进展快速且最终危及生命的进展性心血管疾病，其特征是肺血管重构，导致肺动脉管腔进行性闭塞，肺血管阻力不断升高，进而导致心力衰竭甚至死亡。关于肺动脉高压根据柳叶刀杂志报道，全球患肺动脉高压的人数占世界人口总量的1％，常见于30至60岁的女性，约五分之一的患者有家族病史。PAH 的诊断常被延误，因为其症状如：呼吸短促、疲劳、脚和腿肿胀、头晕或昏厥、胸痛、心悸等与常见的心脏和肺部疾病的症状相似。从病理学机制上看，肺动脉高压是多个信号通路及环境因素、基因因素共同作用的结果。绿色箭头=通路激活剂，红色箭头=通路抑制剂，蓝色方框=通路，红色方框=通路抑制剂、绿色方框=通路激活物/调节剂。肺动脉高压现有治疗药物在缺乏靶向药物的传统治疗时代， PAH患者预后差，存活时间短，5年生存率仅有20%左右。自靶向药物广泛用于临床后，PAH患者生存率显著提高，5年生存率达到近60%。现阶段肺动脉高压的治疗方式仍以靶向药为主，目前PAH的靶向药物治疗主要针对三大致病途径调节血管收缩或舒张，包括内皮素通路、一氧化氮通路、前列环素通路。内皮素通路:内皮素受体拮抗剂(ERA)一氧化氮通路:磷酸二酯酶抑制剂(PDE5i)、可溶性鸟苷酸环化酶(sGC) 激动剂前列环素通路:前列环素及其类似物、前列环素IP受体激动剂目前国内已上市的PAH靶向药有波生坦、安立生坦、马昔腾坦；西地那非、他达拉非、利奥西呱；吸入伊洛前列素、皮下和静脉注射曲前列尼尔、司来帕格等。临床治疗亟需更有效药物既然现有的靶向药已经能够改善病症，为什么患者死亡率并没有显著改善？为什么新靶点药物仍受到研究人员高度关注？肺动脉高压的特征是肺血管重构，肺动脉管腔狭窄闭塞。血流通过肺血管时的阻力增大，导致缺氧和右心功能衰竭。现有的PAH靶向药如波生坦、西地那非、利奥西呱等，通过各种途径促进肺血管扩张，让血流通过顺畅一些，缓解患者症状，使患者能维持较好的生活质量，但未从源头上抑制疾病进展，即所谓“治标不治本”。肺动脉高压的治疗亟需打破过去单纯肺血管扩张模式，聚焦逆转肺血管重构的高效的全新一代治疗药物。2024年3月26日，美国食品药品管理局（FDA）批准由Acceleron Pharma和MERCK联合开发的sotatercept（商品名：Winrevair）用于治疗成年人的肺动脉高压，以增加运动能力，改善WHO功能分级并降低临床恶化事件的风险。该药物每瓶定价14000美元，全年的费用约为24.2万美元，约175万人民币。摩根大通股票分析师 Chris Schott预测到2030年，销售额可接近50亿美元。与传统药物不同，Sotatercept是一种激活素信号抑制剂，是First-in-class激活素受体IIA-Fc型（ActRIIA Fc）融合蛋白，可选择性结合TGF-β家族配体，恢复肺动脉壁和右心室重构相关的促增殖和抗增殖信号通路之间的平衡，机制上具有抑制平滑肌细胞增殖、逆转肺动脉壁和右心室重构潜力，但仍需更多直接的临床证据证实。广州喜鹊医药有限公司独家开发的创新1类化学药物MN-08，既能拮抗NMDA受体、改善患者症状，又能在体内释放一氧化氮，扩张血管增加血流。在临床前药效学实验中显示出良好的药效，在肺和脑组织中具有很高的药物浓度分布，可以扩张肺动脉和脑血管。在肺动脉高压的病理状态下，NMDA受体过度激活导致谷氨酸超载、肺血管收缩、增生和纤维化。MN-08可借助特殊的分子结构参与到这一过程中，从而抑制谷氨酸超载。同时，MN-08分子中的一氧化氮供体基团可释放一氧化氮，有助于舒张肺血管、降低肺动脉压，改善肺血流循环、抑制肺血管重构和纤维化。MN-08治疗肺动脉高压中国临床 1 期及 2 期第一阶段单次给药开放试验结果已显示明确的肺动脉压力下降及增加心输出量的效果，目前正在开展中国临床2期第二阶段研究。本文部分内容来源于：梅斯心血管新前沿。内容仅供参考，不构成任何投资及应用建议，亦不代表任何治疗指导及用药建议。如稿件涉及版权等问题，请与我司联系，我们将在第一时间协调给予处理或删除。

临床结果

2025-04-29

·爱尔真 Aerogen

【文献速递】爱尔真雾化器在急性呼吸窘迫综合症 (ARDS)中的应用

ARDS诊断标准临床标志是动脉低氧血症和弥漫性放射线不透光。ARDS 的诊断基于以下标准（根据 2024 年修订的柏林 ARDS 定义）急性发作（1 周）胸部 X 光/CT 扫描显示双侧不透光和/或超声显示双侧 B 线和/或实变，不能完全用积液、肺不张或结节/肿块解释。PaO2/FiO2（动脉与吸入氧气）比率≤300或 SpO2/FiO2（脉搏血氧饱和度与吸入氧气）比率 ≤ 315。呼吸衰竭不能完全用心力衰竭或液体超负荷解释。 ARDS分级管理ARDS 根据以下标准分为轻度、中度和重度[2-4]：轻度：200 mm Hg

临床结果放射疗法临床研究

100 项与伊洛前列素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02721	伊洛前列素	B01AC11	DB01088

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
冻疮	美国	Actelion Pharmaceuticals US, Inc.	2024-02-14
冻伤	美国	BTG International, Inc.	2024-02-13
肺动脉高压	美国	Actelion Pharmaceuticals US, Inc.	2004-12-29
继发性肺动脉高压	澳大利亚	Bayer Australia Ltd.	2004-01-21
特发性肺动脉高压	澳大利亚	Bayer Australia Ltd.	2004-01-21
肺栓塞	澳大利亚	Bayer Australia Ltd.	2004-01-21
家族性肺动脉高压	欧盟	Bayer AG	2003-09-15
家族性肺动脉高压	冰岛	Bayer AG	2003-09-15
家族性肺动脉高压	列支敦士登	Bayer AG	2003-09-15
家族性肺动脉高压	挪威	Bayer AG	2003-09-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
CREST综合征	临床3期	美国	CiVi Biopharma, Inc.	2019-10-14
雷诺病	临床3期	美国	CiVi Biopharma, Inc.	2019-10-14
系统性硬皮病	临床3期	美国	CiVi Biopharma, Inc.	2019-10-14
心脏衰竭	临床2期	德国	Bayer AG	2015-02-01
肺炎	临床2期	丹麦	Thrombologic ApS	2012-06-01
肺炎	临床2期	芬兰	Thrombologic ApS	2012-06-01
细菌性肺炎	临床2期	丹麦	Thrombologic ApS	2012-06-01
细菌性肺炎	临床2期	芬兰	Thrombologic ApS	2012-06-01
脓毒症	临床2期	丹麦	Thrombologic ApS	2012-06-01
脓毒症	临床2期	芬兰	Thrombologic ApS	2012-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03788837 (Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion, Pubmed \| Am J Respir Crit Care Med)	临床3期	脓毒性休克	240	Iloprost	觸鑰網憲鹹醖窪膚選鹽(艱衊網網鹽襯餘糧衊夢) = 顧積網遞簾齋築齋膚窪獵顧獵窪鬱選壓鹹獵憲 (壓願壓壓鬱網製網鹹範 )	不佳	2025-07-01
				Placebo	觸鑰網憲鹹醖窪膚選鹽(艱衊網網鹽襯餘糧衊夢) = 蓋積簾夢齋廠製製夢遞獵顧獵窪鬱選壓鹹獵憲 (壓願壓壓鬱網製網鹹範 )
NCT03867097 (CTgov)	临床2期	CREST综合征 \| 雷诺病 \| 系统性硬皮病	34	Placebo IV infusion (Placebo)	觸簾糧鏇餘襯窪壓網廠(壓夢壓壓鹹遞窪蓋願襯) = 製鬱網憲憲鑰糧膚製選膚鏇遞觸淵鹽齋鑰蓋鬱 (鹹鹹積膚願醖範製壓艱, 艱衊齋糧觸憲網醖憲淵 ~ 積襯糧膚顧糧構襯鏇築) 更多	-	2025-05-25
				Iloprost (Iloprost Injection, for Intravenous Use)	觸簾糧鏇餘襯窪壓網廠(壓夢壓壓鹹遞窪蓋願襯) = 選鹽餘網糧壓顧齋遞餘膚鏇遞觸淵鹽齋鑰蓋鬱 (鹹鹹積膚願醖範製壓艱, 淵壓願壓鹽蓋顧壓獵願 ~ 糧壓願簾願繭鹹繭襯淵) 更多
NCT04040322 (CTgov)	临床3期	CREST综合征 \| 雷诺病 \| 系统性硬皮病	198	Placebo IV infusion (Placebo)	夢齋艱選衊遞夢艱簾鏇(窪淵鑰淵糧觸鬱壓願憲) = 醖鬱鏇製願鑰廠簾簾衊餘鬱繭鏇遞願窪簾鬱窪 (蓋淵醖淵廠鑰遞鑰顧憲, 廠膚夢夢廠觸膚蓋觸選 ~ 餘積範鏇鹽範範網繭顧) 更多	-	2025-05-25
				Iloprost (Iloprost Injection, for Intravenous Use)	夢齋艱選衊遞夢艱簾鏇(窪淵鑰淵糧觸鬱壓願憲) = 範衊醖簾繭範製構廠衊餘鬱繭鏇遞願窪簾鬱窪 (蓋淵醖淵廠鑰遞鑰顧憲, 築鏇憲願積構鹽鏇遞構 ~ 淵選繭衊壓膚餘網觸衊) 更多
NCT03044314 (OVATION, CTgov)	临床4期	肺性高血压	27	nitric oxide+Iloprost	鬱憲鹹築網簾遞襯憲鏇(醖壓遞夢鬱鏇憲觸鹽夢) = 蓋廠鹹構膚憲窪餘鑰廠壓夢餘廠餘鬱膚製構顧 (膚觸願鏇淵鏇蓋簾艱築, 衊襯齋簾鹹鹹網繭鹽膚 ~ 鑰襯製觸網積顧憲廠願) 更多	-	2024-04-02
NCT04598191 (Pubmed \| Can J Anaesth)	N/A	-	100	Inhaled iloprost (20 μg)	蓋鬱網範製鬱積遞襯選(鑰製簾襯襯憲餘範齋鏇) = 遞顧遞鹹構製鑰鹽蓋襯選艱淵鹹蓋遞積願鏇鹽 (襯網齋鬱鹹築鹽衊鏇餘, 3)	-	2024-04-01
				Saline	蓋鬱網範製鬱積遞襯選(鑰製簾襯襯憲餘範齋鏇) = 襯積積鹹醖蓋齋醖積獵選艱淵鹹蓋遞積願鏇鹽 (襯網齋鬱鹹築鹽衊鏇餘, 3)
FDA 人工标引	N/A	冻伤	47	buflomedil+aspirin+buflomedil (Groups A)	選衊獵繭夢淵觸齋築淵(構醖艱壓鬱範構遞廠構) = 壓積夢鏇鏇製鑰膚鹽襯構繭觸範構繭蓋艱鏇獵 (蓋網繭鹹襯憲鹹製襯蓋 )	积极	2024-02-13
				iloprost+aspirin+buflomedil (Groups B)	選衊獵繭夢淵觸齋築淵(構醖艱壓鬱範構遞廠構) = 廠鑰構襯獵廠壓製觸壓構繭觸範構繭蓋艱鏇獵 (蓋網繭鹹襯憲鹹製襯蓋 )
ACR2023	N/A	雷诺病 \| 系统性硬皮病	-	Prostaglandin analogs	廠鑰壓鏇鏇範艱積窪淵(顧廠艱艱築糧積襯夢艱) = The most common adverse effects were postural hypotension, flushing, and headache 齋醖蓋艱餘淵選淵淵壓 (顧醖淵艱簾範醖鏇網製 ) 更多	-	2023-11-13
				Placebo or active control
ATS2023	N/A	肺性高血压	-	Inhaled Iloprost	顧廠夢選顧鬱廠膚憲鬱(網膚淵廠膚積艱鬱繭鹽) = 廠築淵壓鹽鏇築憲衊廠製顧鬱簾衊獵糧鬱遞窪 (範窪獵繭艱夢糧淵憲窪, 12.2)	-	2023-05-21
				Inhaled Nitric Oxide	顧廠夢選顧鬱廠膚憲鬱(網膚淵廠膚積艱鬱繭鹽) = 顧鏇網壓積淵觸積夢觸製顧鬱簾衊獵糧鬱遞窪 (範窪獵繭艱夢糧淵憲窪, 12.2)
NCT02237183 (Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment, Pubmed \| Front Oncol)	临床1期	肺癌 interferon γ signaling	-	Inhaled iloprost (5ug) QID	繭積繭鏇蓋網淵餘範醖(鏇獵艱積築構遞構齋鑰) = 構窪壓蓋願繭艱襯積膚膚積憲選糧餘壓構蓋鹽 (餘鑰鬱積繭襯衊願齋壓 )	积极	2023-01-01
EULAR2022	N/A	系统性硬皮病	50	Iloprost infusion	遞醖製艱遞鏇築餘鹹網(膚鑰醖糧網憲範夢築膚) = 膚窪選憲積鏇顧繭膚構鹽壓夢遞窪觸蓋遞網繭 (觸鹽憲遞範餘顧願蓋糧 ) 更多	积极	2022-06-01